The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of bevacizumab, cisplatin, and pemetrexed in Japanese patients with advanced nonsquamous non-small cell lung cancer.
Noriko Yanagitani
No relevant relationships to disclose
Fumiyoshi Ohyanagi
No relevant relationships to disclose
Hironari Nishizawa
No relevant relationships to disclose
Hiroshi Gyotoku
No relevant relationships to disclose
Takeshi Uenami
No relevant relationships to disclose
Hiroshi Kobayashi
No relevant relationships to disclose
Keita Kudo
No relevant relationships to disclose
Yuichi Tambo
No relevant relationships to disclose
Atsushi Horiike
No relevant relationships to disclose
Sachiko Hagiwara
No relevant relationships to disclose
Takeshi Horai
No relevant relationships to disclose
Makoto Nishio
Honoraria - Chugai Pharma; Lilly